| About the Editors |
|
xiii | |
| Contributors |
|
xv | |
| Foreword |
|
xvii | |
| Introduction |
|
1 | (4) |
|
|
|
| PART I: HISTORICAL NOTES |
|
|
Chapter
1. The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine |
|
|
5 | (8) |
|
|
|
|
|
|
5 | (1) |
|
|
|
6 | (1) |
|
|
|
6 | (4) |
|
|
|
10 | (2) |
|
|
|
12 | (1) |
|
Chapter
2. Cognoscenti of Cannabis I: Jacques-Joseph Moreau (1804-1884) |
|
|
13 | (4) |
|
|
|
|
Chapter
3. Cognoscenti of Cannabis II: Simeon Seth on Cannabis |
|
|
17 | (6) |
|
|
|
|
Chapter
4. The Medical Use of Cannabis Among the Greeks and Romans |
|
|
23 | (20) |
|
|
|
|
|
|
23 | (1) |
|
|
|
24 | (1) |
|
The Emergence of Cannabis |
|
|
25 | (15) |
|
Appendix I: Passages Discussing Wild Cannabis Possibly Misunderstood As Discussing Domesticated Cannabis |
|
|
40 | (1) |
|
Appendix II: Cannabis in Veterinary Medicine |
|
|
41 | (1) |
|
|
|
42 | (1) |
|
Chapter
5. A Homelie Herbe: Medicinal Cannabis in Early England |
|
|
43 | (10) |
|
|
|
|
|
|
43 | (2) |
|
Cannabis History in England |
|
|
45 | (4) |
|
|
|
49 | (2) |
|
|
|
51 | (2) |
|
Chapter
6. Future of Cannabis and Cannabinoids in Therapeutics |
|
|
53 | (16) |
|
|
|
|
|
|
53 | (3) |
|
New Indications for Cannabinoid Pharmaceuticals |
|
|
56 | (1) |
|
Cannabinoids and Neuroprotection |
|
|
57 | (1) |
|
|
|
58 | (1) |
|
|
|
58 | (5) |
|
|
|
63 | (6) |
| PART II: PHARMACOLOGY AND PHARMACOKINETICS |
|
|
Chapter
7. Clinical Pharmacokinetics of Cannabinoids |
|
|
69 | (48) |
|
|
|
|
|
|
69 | (5) |
|
Pharmacokinetics of Δ9-THC |
|
|
74 | (1) |
|
|
|
75 | (5) |
|
|
|
80 | (4) |
|
|
|
84 | (2) |
|
Course of Plasma Concentration of THC and Metabolites |
|
|
86 | (2) |
|
|
|
88 | (6) |
|
|
|
94 | (5) |
|
Pharmacokinetics of Other Cannabinoids |
|
|
99 | (2) |
|
|
|
101 | (2) |
|
|
|
103 | (14) |
|
Chapter
8. Clinical Pharmacodynamics of Cannabinoids |
|
|
117 | (54) |
|
|
|
|
|
|
117 | (2) |
|
|
|
119 | (2) |
|
|
|
121 | (1) |
|
|
|
122 | (3) |
|
Pharmacological Effects of THC |
|
|
125 | (1) |
|
|
|
125 | (2) |
|
Psyche, Cognition and Behavior |
|
|
127 | (1) |
|
Central Nervous System and Neurochemistry |
|
|
128 | (2) |
|
|
|
130 | (1) |
|
Some Other Organ Systems and Effects |
|
|
131 | (2) |
|
Pharmacological Activity of THC Metabolites |
|
|
133 | (2) |
|
Pharmacological Effects of Other Cannabinoids |
|
|
135 | (3) |
|
|
|
138 | (1) |
|
|
|
139 | (1) |
|
Hierarchy of Therapeutic Effects |
|
|
140 | (1) |
|
|
|
141 | (2) |
|
|
|
143 | (1) |
|
|
|
144 | (21) |
|
|
|
165 | (6) |
|
Chapter
9. Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? |
|
|
171 | (36) |
|
|
|
|
|
|
|
|
|
171 | (1) |
|
|
|
172 | (1) |
|
|
|
172 | (1) |
|
|
|
173 | (5) |
|
|
|
178 | (9) |
|
|
|
187 | (3) |
|
|
|
190 | (11) |
|
|
|
201 | (6) |
| PART III: ENDOCANNABINOMS AND CANNABINOID RECEPTORS |
|
|
Chapter
10. The Endocannabinoid System: Can It Contribute to Cannabis Therapeutics? |
|
|
207 | (20) |
|
|
|
|
The Endocannabinoid System |
|
|
207 | (2) |
|
Endocannabinoid Pharmacology: More Than Meets the Eye |
|
|
209 | (2) |
|
Levels of Endocannabinoids in Tissues: Physiology and Pathology |
|
|
211 | (5) |
|
New Drugs From the Endocannabinoid System: Curative or Palliative? |
|
|
216 | (9) |
|
|
|
225 | (2) |
|
Chapter
11. Cannabinoids and Feeding: The Role of the Endogenous Cannabinoid System As a Trigger for Newborn Suckling |
|
|
227 | (16) |
|
|
|
|
Interactions of the Endocannabinoid System with Hormones Regulating Food Intake |
|
|
228 | (1) |
|
Endocannabinoids in Food Substances |
|
|
229 | (1) |
|
Developmental Aspects of the Endocannabinoid-CB1 Receptor System |
|
|
230 | (1) |
|
Blockade of CB1 Receptors in Newborn Mice |
|
|
231 | (2) |
|
Mechanisms of the CB1 Receptor Blockade-Induced Growth-Stunting Effects |
|
|
233 | (1) |
|
|
|
234 | (4) |
|
|
|
238 | (5) |
| PART IV: MEDICINAL USES |
|
|
Chapter
12. Marijuana (Cannabis) As Medicine |
|
|
243 | (22) |
|
|
|
|
|
|
243 | (2) |
|
Indications with Evidence for Medical Efficacy |
|
|
245 | (8) |
|
Indications with Sparse Evidence of Efficacy |
|
|
253 | (4) |
|
|
|
257 | (1) |
|
|
|
258 | (5) |
|
|
|
263 | (2) |
|
Chapter
13. Effects of Smoked Cannabis and Oral S-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy: A Review of State Clinical Trials |
|
|
265 | (16) |
|
|
|
|
|
|
|
|
|
266 | (1) |
|
|
|
267 | (1) |
|
|
|
268 | (2) |
|
|
|
270 | (1) |
|
|
|
271 | (1) |
|
|
|
272 | (1) |
|
|
|
273 | (2) |
|
|
|
275 | (3) |
|
|
|
278 | (3) |
|
Chapter
14. Hyperemesis Gravidarum and Clinical Cannabis: To Eat or Not to Eat? |
|
|
281 | (22) |
|
|
|
|
HG, Its Medicalization, and the Survivors |
|
|
282 | (6) |
|
Cannabis, Pregnancy, and HG |
|
|
288 | (5) |
|
Two Women's Stories of Using Folk, Alternative Medicine |
|
|
293 | (4) |
|
|
|
297 | (5) |
|
|
|
302 | (1) |
|
Chapter
15. Therapeutic Cannabis (Marijuana) As an Antiemetic and Appetite Stimulant in Persons with Acquired Immunodeficiency Syndrome |
|
|
303 | (12) |
|
|
|
|
AIDS in the United States |
|
|
303 | (2) |
|
Cannabinoids as Antiemetic and Appetite Stimulant in AIDS Wasting Syndrome |
|
|
305 | (1) |
|
Case Reports (The Patients' Perspective) |
|
|
306 | (2) |
|
Recent Clinical Research on Cannabinoids, Immunity, and Weight Gain |
|
|
308 | (1) |
|
Cannabis and Harm Reduction Strategies for Persons with AIDS |
|
|
308 | (3) |
|
|
|
311 | (2) |
|
|
|
313 | (2) |
|
Chapter
16. Cannabis Treatments in Obstetrics and Gynecology: A Historical Review |
|
|
315 | (32) |
|
|
|
|
|
|
315 | (1) |
|
The Ancient World and Medieval Middle and Far East |
|
|
315 | (3) |
|
European and Western Medicine |
|
|
318 | (13) |
|
Modern Ethnobotany of Cannabis in Obstetrics and Gynecology |
|
|
331 | (3) |
|
Recent Theory and Clinical Data |
|
|
334 | (4) |
|
Discussion and Conclusions |
|
|
338 | (7) |
|
|
|
345 | (2) |
|
Chapter
17. Crack Heads and Roots Daughters: The Therapeutic Use of Cannabis in Jamaica |
|
|
347 | (16) |
|
|
|
|
|
|
348 | (2) |
|
|
|
350 | (1) |
|
|
|
351 | (6) |
|
|
|
357 | (1) |
|
|
|
358 | (2) |
|
|
|
360 | (3) |
|
Chapter
18. Cannabis in Multiple Sclerosis: Women's Health Concerns |
|
|
363 | (20) |
|
|
|
|
|
|
363 | (1) |
|
Treatment Options: Acute Episodes, Disease Modification and Symptom Management |
|
|
364 | (1) |
|
Cannabis in Acute Treatment and Disease Modification |
|
|
365 | (2) |
|
Cannabis in Symptom Management |
|
|
367 | (1) |
|
Impaired Mobility: Spasticity |
|
|
368 | (1) |
|
|
|
369 | (1) |
|
|
|
369 | (1) |
|
|
|
370 | (1) |
|
|
|
370 | (1) |
|
|
|
371 | (1) |
|
|
|
371 | (1) |
|
|
|
372 | (5) |
|
|
|
377 | |
|
|
|
373 | (4) |
|
|
|
377 | (6) |
| PART V: SIDE EFFECTS |
|
|
Chapter
19. Cannabis and Harm Reduction: A Nursing Perspective |
|
|
383 | (16) |
|
|
|
|
|
|
383 | (2) |
|
Cannabis Was a Medicine in the United States |
|
|
385 | (1) |
|
Cannabis As a Harm Reduction Medicine |
|
|
386 | (3) |
|
Cannabis As a Social/Recreational Drug |
|
|
389 | (4) |
|
Cannabis Prohibition Causes More Harm Than the Drug |
|
|
393 | (3) |
|
|
|
396 | (3) |
|
Chapter
20. Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An Examination of Benefits and Adverse Effects of Legal Clinical Cannabis |
|
|
399 | (50) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400 | (1) |
|
Previous Chronic Cannabis Use Studies |
|
|
400 | (1) |
|
A Brief History of the Compassionate IND |
|
|
401 | (2) |
|
|
|
403 | (1) |
|
|
|
404 | (38) |
|
Conclusions and Recommendations |
|
|
442 | (5) |
|
|
|
447 | (2) |
| Afterword |
|
449 | (2) |
| Index |
|
451 | |
Daugiau apie elektronines knygas